Clinical trial SY-1425-301
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of SY-1425 Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, RARA-positive Adult Patients with Higher-risk Myelodysplastic Syndrome
| Cancers | |
|---|---|
| Organ | Syndromes myélodysplasiques (MSD) |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | SYROS Pharmaceuticals, Inc |
| EudraCT Identifier | 2020-004528-40 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04797780 |
| Inclusion criteria | RARA-positive, Newly diagnosed with HR-MDS, bone marrow blasts > 5%, adequate organ function |
| Last update |